GB2230439A - Nicotine lozenges - Google Patents
Nicotine lozenges Download PDFInfo
- Publication number
- GB2230439A GB2230439A GB8908928A GB8908928A GB2230439A GB 2230439 A GB2230439 A GB 2230439A GB 8908928 A GB8908928 A GB 8908928A GB 8908928 A GB8908928 A GB 8908928A GB 2230439 A GB2230439 A GB 2230439A
- Authority
- GB
- United Kingdom
- Prior art keywords
- lozenge
- nicotine
- lozenges
- shell
- coating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000007937 lozenge Substances 0.000 title claims abstract description 38
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 title claims abstract description 17
- 229960002715 nicotine Drugs 0.000 title claims abstract description 17
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 title claims abstract description 17
- 239000011248 coating agent Substances 0.000 claims abstract description 18
- 238000000576 coating method Methods 0.000 claims abstract description 18
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 claims abstract description 8
- 230000000202 analgesic effect Effects 0.000 claims abstract description 5
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000005770 Eugenol Substances 0.000 claims abstract description 4
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229960002217 eugenol Drugs 0.000 claims abstract description 4
- 235000002637 Nicotiana tabacum Nutrition 0.000 abstract description 3
- 230000000391 smoking effect Effects 0.000 abstract description 3
- 241000208125 Nicotiana Species 0.000 abstract description 2
- 230000002738 anti-smoking effect Effects 0.000 abstract description 2
- 238000000034 method Methods 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 235000020374 simple syrup Nutrition 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- 244000223014 Syzygium aromaticum Species 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000019788 craving Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 239000000565 sealant Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 235000021092 sugar substitutes Nutrition 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000019505 tobacco product Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A lozenge which is a substitute for smoking tobacco comprises a lozenge core which contains nicotine and/or a nicotine substitute, and a shell or coating around the lozenge core. The shell or coating may comprise an oral-acting, local analgesic, for example eugenol. Such lozenges are more palatable than known anti-smoking lozenges, and are more stable against humidity and loss of the nicotine or nicotine substitute.
Description
NICOTINE LOZENGES
This invention concerns nicotine or nicotinesubstitute lozenges, and more particularly a nicotine or nicotine-substitute containing lozenge which can be dissolved in the mouth to satisfy a craving for tobacco, either as an aid in stopping the habit of smoking or as a substitute for cigarettes or other smokable tobacco products in areas where smoking is dangerous or prohibited.
According to the present invention there is provided a lozenge which contains nicotine or a nicotinesubstitute, the lozenge comprising a lozenge core which contains nicotine and/or a nicotine substitute, and a shell or coating around the lozenge core.
Conventional methods may be employed to provide a shell or coating, which may suitably be a sugar or sugar-substitute shell or coating, around the lozenge core. One suitable method is pan-coating whereby the lozenge cores are introduced into a rotating pan, and are sprayed with an initial, sealant layer, which may comprise, for example, shellac or glycerine, then removed and dried, then returned to the pan for coating with a syrup, prior to final drying and polishing. Another available method, known as dry coating by compression, involves the pressing together of pre-formed shell halves around the lozenge core.
The shell or coating may contain any desired flavouring agent.
The shell or coating may comprise an oral-acting, local analgesic. A herbal analgesic, for example eugenol (oil of cloves), is preferred.
Lozenges in accordance with the invention are more palatable than known anti-smoking lozenges because of the shell or coating, the flavouring thereof being untainted by the flavour of nicotine or a nicotinesubstitute. This effect is very marked initially and persists to a useful extent once the shell or coating has dissolved, due to the residual flavour in the mouth from the shell or coating. The sensation of burning in the mouth which may be experienced with conventional lozenges is substantially ameliorated with lozenges in accordance with the invention. Moreover, lozenges in accordance with the invention are more stable against humidity and escape of nicotine or nicotine-substitute than known lozenges, and will have a longer shelf-life.
The lozenge core may be of a conventional composition, as used for known, uncoated lozenges. A preferred composition is as claimed and described in
U.K. Patent No. 2142822 and U.S. Patent No. 4806356, the contents of which are incorporated herein by reference.
In accordance with a second aspect of the present invention there is provided a process for the preparation of lozenges as described.
The invention will now be further described, by way of example, only, with reference to the following:
A lozenge core is made up in accordance with the detailed description in U.S. Patent No. 4806356. Thus, a sweetened filler is made up; a binder is made up; and a solution of nicotine in alcohol is prepared, as a tobacco plant extraction. The three components are mixed to give, without the application of heat, a preparation which is then formed into tablets which will form the lozenge cores.
A large number of lozenge cores is conveyed to a coating pan which is rotated and agitated whilst a glycerine spray is applied. The lozenge cores are removed and dried, then returned to the coating pan, for application of a sugar syrup, containing, in this case, an orange colouring agent. The lozenges are dried and finally polished.
In another embodiment the sugar syrup incorporates eugenol, to act as an oral local analgesic.
The resultant lozenges dissolve slowly in the mouth releasing the nicotine contained in the lozenge cores gradually for absorbtion within the buccal cavity.
The reader's attention is directed to all papers and documents which are filed concurrently with this specification, and which are open to public inspection with this specification and the contents of all such papers and documents are incorporated herein by reference.
All of the features disclosed in this specification (including any accompanying claims, abstract and drawings), and/or all of the steps of any method or process so disclosed, may be combined in any combination, except combinations where at least some of such features and/or steps are mutually exclusive.
Each feature disclosed in the specification (including any accompanying claims, abstract and drawings), may be replaced by alternative features serving the same, equivalent or similar purpose, unless expressly stated otherwise. Thus, unless expressly stated otherwise, each feature disclosed is one example only of a generic series of equivalent or similar features.
The invention is not restricted to the details of the foregoing embodiment(s). The invention extends to any novel one, or any novel combination, of the features disclosed in this specification (including any accompanying claims, abstract and drawings), or to any novel one, or any novel combination, of the steps of any method or process so disclosed.
Claims (4)
1. A lozenge comprising a lozenge core which contains nicotine and/or a nicotine substitute, and a shell or coating around the lozenge core.
2. A lozenge as claimed in Claim 1, wherein the shell or coating comprises an oral-acting, local analgesic.
3. A lozenge as claimed in Claim 2, wherein the shell or coating comprises eugenol.
4. A lozenge substantially as hereinbefore described with reference to the Example.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8908928A GB2230439A (en) | 1989-04-20 | 1989-04-20 | Nicotine lozenges |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8908928A GB2230439A (en) | 1989-04-20 | 1989-04-20 | Nicotine lozenges |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB8908928D0 GB8908928D0 (en) | 1989-06-07 |
| GB2230439A true GB2230439A (en) | 1990-10-24 |
Family
ID=10655351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB8908928A Withdrawn GB2230439A (en) | 1989-04-20 | 1989-04-20 | Nicotine lozenges |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB2230439A (en) |
Cited By (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5362496A (en) * | 1993-08-04 | 1994-11-08 | Pharmetrix Corporation | Method and therapeutic system for smoking cessation |
| WO1995011679A1 (en) * | 1993-10-28 | 1995-05-04 | Dynagen, Inc. | Use of lobeline for the treatment of nicotine withdrawal |
| US5549906A (en) * | 1993-07-26 | 1996-08-27 | Pharmacia Ab | Nicotine lozenge and therapeutic method for smoking cessation |
| AU681323B1 (en) * | 1996-04-19 | 1997-08-21 | University Of Utah Research Foundation | Tobacco substitute |
| US5783207A (en) * | 1985-05-01 | 1998-07-21 | University Of Utah Research Foundation | Selectively removable nicotine-containing dosage form for use in the transmucosal delivery of nicotine |
| US5824334A (en) * | 1989-09-05 | 1998-10-20 | University Of Utah Research Foundation | Tobacco substitute |
| WO1999015171A1 (en) * | 1997-09-25 | 1999-04-01 | Pharmacia & Upjohn Ab | Nicotine compositions and methods of formulation thereof |
| US6893654B2 (en) * | 1998-09-03 | 2005-05-17 | Jsr, Llc | Two-stage transmucosal medicine delivery system for symptom relief |
| WO2007143367A1 (en) * | 2006-05-31 | 2007-12-13 | Wm. Wrigley Jr. Company | Coated confectionery compositions and methods regarding same |
| WO2011101860A1 (en) | 2010-02-18 | 2011-08-25 | Jatin Vasant Thakkar | Nicotine-containing soft gelatin pastilles |
| WO2013103318A1 (en) * | 2012-01-05 | 2013-07-11 | Mcneil Ab | Solid nicotine-comprising dosage form with reduced organoleptic disturbance |
| US8642016B2 (en) | 2006-07-21 | 2014-02-04 | Jsrnti, Llc | Medicinal delivery system, and related methods |
| US20150157620A1 (en) * | 2012-07-30 | 2015-06-11 | Pierre Fabre Medicament | Lozenges with multiple release kinetics for active ingredients |
| US10213586B2 (en) | 2015-01-28 | 2019-02-26 | Chrono Therapeutics Inc. | Drug delivery methods and systems |
| US10258778B2 (en) | 2004-09-13 | 2019-04-16 | Chrono Therapeutics Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
| US10653686B2 (en) | 2011-07-06 | 2020-05-19 | Parkinson's Institute | Compositions and methods for treatment of symptoms in parkinson's disease patients |
| US10679516B2 (en) | 2015-03-12 | 2020-06-09 | Morningside Venture Investments Limited | Craving input and support system |
| US10716764B2 (en) | 2003-10-27 | 2020-07-21 | Morningside Venture Investments Limited | Transdermal drug delivery method and system |
| US11285306B2 (en) | 2017-01-06 | 2022-03-29 | Morningside Venture Investments Limited | Transdermal drug delivery devices and methods |
| US11596779B2 (en) | 2018-05-29 | 2023-03-07 | Morningside Venture Investments Limited | Drug delivery methods and systems |
| EP4072330B1 (en) | 2019-12-09 | 2024-12-11 | Nicoventures Trading Limited | Oral products with reduced irritation |
| US12397141B2 (en) | 2018-11-16 | 2025-08-26 | Morningside Venture Investments Limited | Thermally regulated transdermal drug delivery system |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2608156A1 (en) * | 1986-12-12 | 1988-06-17 | Ethypharm Sa | CHEWING GUM FOR FREEING FROM TOBACCO |
-
1989
- 1989-04-20 GB GB8908928A patent/GB2230439A/en not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2608156A1 (en) * | 1986-12-12 | 1988-06-17 | Ethypharm Sa | CHEWING GUM FOR FREEING FROM TOBACCO |
Non-Patent Citations (2)
| Title |
|---|
| THE PHARMACE * |
| THEORY AND P * |
Cited By (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5783207A (en) * | 1985-05-01 | 1998-07-21 | University Of Utah Research Foundation | Selectively removable nicotine-containing dosage form for use in the transmucosal delivery of nicotine |
| US5824334A (en) * | 1989-09-05 | 1998-10-20 | University Of Utah Research Foundation | Tobacco substitute |
| US6280761B1 (en) | 1993-07-26 | 2001-08-28 | Pharmacia Ab | Nicotine lozenge |
| US5549906A (en) * | 1993-07-26 | 1996-08-27 | Pharmacia Ab | Nicotine lozenge and therapeutic method for smoking cessation |
| US5662920A (en) * | 1993-07-26 | 1997-09-02 | Pharmacia Ab | Nicotine lozenge and therapeutic method for smoking cessation |
| US5593684A (en) * | 1993-08-04 | 1997-01-14 | Pharmacia Ab | Method and therapeutic system for smoking cessation |
| US5362496A (en) * | 1993-08-04 | 1994-11-08 | Pharmetrix Corporation | Method and therapeutic system for smoking cessation |
| WO1995011679A1 (en) * | 1993-10-28 | 1995-05-04 | Dynagen, Inc. | Use of lobeline for the treatment of nicotine withdrawal |
| WO1995011678A1 (en) * | 1993-10-28 | 1995-05-04 | Dynagen, Inc. | Use of nicotine substitutes for the treatment of nicotine withdrawal |
| AU681323B1 (en) * | 1996-04-19 | 1997-08-21 | University Of Utah Research Foundation | Tobacco substitute |
| RU2201747C2 (en) * | 1997-09-25 | 2003-04-10 | Фармасиа АБ | Composition for substituting tobacco, method for producing the composition and method for treating smoking addiction, alzheimer disease, parkinson disease or nonspecific ulcerative colitis |
| WO1999015171A1 (en) * | 1997-09-25 | 1999-04-01 | Pharmacia & Upjohn Ab | Nicotine compositions and methods of formulation thereof |
| AU733619B2 (en) * | 1997-09-25 | 2001-05-17 | Pharmacia Ab | Nicotine compositions and methods of formulation thereof |
| US6893654B2 (en) * | 1998-09-03 | 2005-05-17 | Jsr, Llc | Two-stage transmucosal medicine delivery system for symptom relief |
| US10716764B2 (en) | 2003-10-27 | 2020-07-21 | Morningside Venture Investments Limited | Transdermal drug delivery method and system |
| US10258738B2 (en) | 2004-09-13 | 2019-04-16 | Chrono Therapeutics Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, AIDs, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
| US10258778B2 (en) | 2004-09-13 | 2019-04-16 | Chrono Therapeutics Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
| US11471424B2 (en) | 2004-09-13 | 2022-10-18 | Morningside Venture Investments Limited | Biosynchronous transdermal drug delivery |
| WO2007143367A1 (en) * | 2006-05-31 | 2007-12-13 | Wm. Wrigley Jr. Company | Coated confectionery compositions and methods regarding same |
| US8642016B2 (en) | 2006-07-21 | 2014-02-04 | Jsrnti, Llc | Medicinal delivery system, and related methods |
| US10799449B2 (en) | 2006-07-21 | 2020-10-13 | Jsrnti, Llc | Medicinal delivery system and related methods |
| US8470366B2 (en) | 2010-02-18 | 2013-06-25 | Jatin Thakkar | Nicotine containing soft gelatin pastilles |
| WO2011101860A1 (en) | 2010-02-18 | 2011-08-25 | Jatin Vasant Thakkar | Nicotine-containing soft gelatin pastilles |
| US10653686B2 (en) | 2011-07-06 | 2020-05-19 | Parkinson's Institute | Compositions and methods for treatment of symptoms in parkinson's disease patients |
| JP2015503581A (en) * | 2012-01-05 | 2015-02-02 | マクニール・アーベーＭｃＮｅｉｌＡＢ | Solid nicotine-containing dosage forms with reduced sensory stimulation |
| WO2013103318A1 (en) * | 2012-01-05 | 2013-07-11 | Mcneil Ab | Solid nicotine-comprising dosage form with reduced organoleptic disturbance |
| US20150157620A1 (en) * | 2012-07-30 | 2015-06-11 | Pierre Fabre Medicament | Lozenges with multiple release kinetics for active ingredients |
| EP2879663B1 (en) * | 2012-07-30 | 2023-07-19 | Pierre Fabre Medicament | Lozenges with multiple release kinetics for active ingredients |
| US11400266B2 (en) | 2015-01-28 | 2022-08-02 | Morningside Venture Investments Limited | Drug delivery methods and systems |
| US10213586B2 (en) | 2015-01-28 | 2019-02-26 | Chrono Therapeutics Inc. | Drug delivery methods and systems |
| US10232156B2 (en) | 2015-01-28 | 2019-03-19 | Chrono Therapeutics Inc. | Drug delivery methods and systems |
| US12011560B2 (en) | 2015-01-28 | 2024-06-18 | Morningside Venture Investments Limited | Drug delivery methods and systems |
| US10679516B2 (en) | 2015-03-12 | 2020-06-09 | Morningside Venture Investments Limited | Craving input and support system |
| US11285306B2 (en) | 2017-01-06 | 2022-03-29 | Morningside Venture Investments Limited | Transdermal drug delivery devices and methods |
| US12042614B2 (en) | 2017-01-06 | 2024-07-23 | Morningside Venture Investments Limited | Transdermal drug delivery devices and methods |
| US12515030B2 (en) | 2017-01-06 | 2026-01-06 | Morningside Venture Investments Limited | Transdermal drug delivery devices and methods |
| US11596779B2 (en) | 2018-05-29 | 2023-03-07 | Morningside Venture Investments Limited | Drug delivery methods and systems |
| US12017029B2 (en) | 2018-05-29 | 2024-06-25 | Morningside Venture Investments Limited | Drug delivery methods and systems |
| US12397141B2 (en) | 2018-11-16 | 2025-08-26 | Morningside Venture Investments Limited | Thermally regulated transdermal drug delivery system |
| EP4072330B1 (en) | 2019-12-09 | 2024-12-11 | Nicoventures Trading Limited | Oral products with reduced irritation |
Also Published As
| Publication number | Publication date |
|---|---|
| GB8908928D0 (en) | 1989-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2230439A (en) | Nicotine lozenges | |
| US4806356A (en) | Tobacco product | |
| US4696315A (en) | Herbal snuff composition | |
| US5417229A (en) | Organoleptic bite composition for human consumption | |
| US6053175A (en) | Method for treating smoking article | |
| KR100296868B1 (en) | Tobacco without nicotine | |
| RU2469625C2 (en) | Smokeless pressed tobacco product for oral consumption | |
| NO863730L (en) | HERBAL CUTTING AND SNOW MATERIALS. | |
| GB2142822A (en) | Nicotine lozenges | |
| BR0209369B1 (en) | smokeless tobacco product. | |
| US6534527B2 (en) | Edible herbal compositions for relieving nicotine craving | |
| CA2443030A1 (en) | Chewable flavor delivery system | |
| US5513663A (en) | Tobacco substitutes | |
| EP4057844A1 (en) | Hot pressed tobacco substrate | |
| EP2170107A2 (en) | Tobacco substitute, and molded tobacco substitute article | |
| US20200337365A1 (en) | Smokable shells with preferably oriented leaves and methods for their preparation | |
| US20200100539A1 (en) | Smokable shells and methods for their preparation | |
| US4813438A (en) | Non-tobacco smoking composition and process for making same | |
| US20040013752A1 (en) | Buccal and sublingual mucosally absorbed herbal compositions for relieving nicotine withdrawal symptoms and craving for nicotine and nicotine containing substances | |
| US160138A (en) | Stephen v | |
| KR102013417B1 (en) | Composition for herbal cigarettes and manufacturing method threrof | |
| US2565052A (en) | Smoking article | |
| KR20220157143A (en) | A tobacco materials and aerosol-generating article comprising the same | |
| US1995069A (en) | Method of making cigarette-cigar | |
| CA1184756A (en) | Substitute smoking tobacco product |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 732 | Registration of transactions, instruments or events in the register (sect. 32/1977) | ||
| WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |